Saffron Perimenopause Trial Explained: What Did the 12-Week Study Find?

One of the more frustrating things about reading supplement research is how easily a promising result turns into a sweeping claim. A headline might say saffron improved mood during perimenopause, but that leaves out the questions that matter when you are making decisions about your own health. Which symptoms actually changed? Did the supplement perform better than a placebo? And was the study testing the same ingredient found in an everyday product, or a specific standardized extract?

The 2021 saffron perimenopause trial randomized 86 women aged 40–60 to receive either a standardized saffron extract or placebo for 12 weeks. The saffron group received 28 mg daily. Researchers found greater improvements in selected psychological symptom scores, but the main repeated-measures analysis of overall menopausal symptoms was not statistically significant. Hot flashes, physical symptoms, and broader quality-of-life measures also showed no clear advantage over placebo.

Imagine a woman in her late forties who has noticed irregular periods, a shorter temper, and nights when she does not feel rested. She sees an impressive percentage about saffron and wonders whether it applies to her. The most useful answer is neither an enthusiastic promise nor a dismissal of botanical research. It is a careful look at what the women in the trial experienced, how the researchers measured it, and where the evidence stops. Those details turn a study headline into information someone can actually use.

What Was the Saffron Perimenopause Trial?

The saffron perimenopause trial was a randomized, double-blind, placebo-controlled study published in the Journal of Menopausal Medicine in 2021. It tested 28 mg of a standardized saffron extract per day for 12 weeks in women experiencing perimenopausal complaints. Researchers tracked psychological, physical, and vasomotor symptoms, along with emotional well-being and quality-of-life measures, to see whether changes differed from those in a placebo group.

Who Participated in the Study?

The researchers enrolled 86 women aged 40–60, assigning 43 to the saffron group and 43 to the placebo group. Participants reported changes in their menstrual cycles for at least three months and had a Greene Climacteric Scale (GCS) total score above 16. Their average ages were approximately 50 years in the saffron group and 49 years in the placebo group. The enrollment criteria deliberately focused on women reporting symptoms rather than selecting people based on age alone.

This distinction matters because perimenopause does not look the same for everyone. One woman may notice occasional irritability and cycle changes, while another experiences frequent hot flashes, poor sleep, and substantial disruption to daily life. The women in this study also needed an intact uterus and ovaries, a body mass index between 18 and 35, and generally no recent medication use apart from limited exceptions. Certain medical and psychiatric conditions were exclusion criteria, making the group more selected than the people who might eventually read about saffron online.

Of the 86 women randomized, 76 completed all study requirements, while self-reported outcome data from 82 women were included in the published analyses. Ten withdrew: four from the saffron group and six from placebo. The researchers retained some participants' earlier questionnaire results in the analysis under their stated missing-data procedure. These are not contradictory totals; randomized, analyzed, and fully completed describe different groups, and confusing them makes the trial appear more straightforward than it actually was.

How Was the Trial Designed?

The experiment lasted 12 weeks and used matching tablets so neither participants nor investigators knew who received the active extract during the trial. Women assigned to saffron took a 14 mg tablet twice a day, providing 28 mg daily, while the comparison group took placebo tablets containing matching nonactive ingredients. Study questionnaires were completed at baseline and at weeks 4, 8, and 12. This repeated schedule allowed the investigators to assess patterns of change rather than relying only on impressions recorded at the end.

Randomization helps distribute personal differences between the groups, and blinding reduces the chance that expectations influence reported experiences. These protections are especially useful in studies of mood and menopausal symptoms, both of which can vary naturally. Yet the design has a practical limit: a short trial using one named extract can establish what was observed under those particular conditions, not whether every saffron product will work in the same way or remain well tolerated after years of use.

The study was prospectively registered as ACTRN12620000350921 and received ethics approval. The original paper, by Adrian L. Lopresti and Stephen J. Smith, is available at the journal's website. Those details make it possible to check the methods and results directly rather than relying on secondhand summaries. They also allow readers to see which measures were planned, how missing responses were handled, and what the researchers themselves described as limitations.

Which Outcomes Did Researchers Measure?

The principal measure was the Greene Climacteric Scale, a 21-question instrument that asks about experiences commonly associated with the menopausal transition. Each item is scored from zero to three, giving a possible total score of 63. Lower scores mean fewer or less severe reported symptoms. Its psychological items address anxiety- and depression-related experiences, while other items cover physical complaints, hot flashes, night sweats, and changes in sexual interest. This division is critical: an improvement in one category does not demonstrate a benefit in all the others.

The researchers also used the Positive and Negative Affect Schedule (PANAS), which asks about different emotional states, and the SF-36 health survey, which measures areas such as vitality, pain, functioning, and emotional well-being. These instruments supplied additional context, but they measured self-reported experiences rather than directly diagnosing a mental health condition. Similarly, the trial did not measure whether saffron normalized estrogen or progesterone or changed the underlying hormonal process of perimenopause. A score moving in a favorable direction is useful information, but it should be read as the specific measurement it is.

Because several questionnaires and subscales were evaluated, the distinction between the primary outcome and secondary findings matters. The study's principal question concerned overall GCS scores; other measures could help explain where a possible effect appeared. If a report quotes only the best-looking outcome while ignoring the primary comparison, it can leave readers with more confidence than the complete set of results supports. A trustworthy interpretation presents the measurements together, including scores that did not show a clear saffron advantage.

What Did the Trial Find?

The trial found greater improvements with saffron than placebo on selected psychological measures, including the GCS psychological subscale and PANAS negative affect. However, the principal repeated-measures comparison of total menopausal symptom scores was not statistically significant. Differences for hot flashes, physical symptoms, and SF-36 quality-of-life measures were also not significant. The most defensible conclusion is a promising mood-related signal, not established relief from perimenopause as a whole.

Did Saffron Improve Mood Scores?

On the GCS psychological subscale, the difference in change between the saffron and placebo groups reached statistical significance, with P = 0.032 and a reported Cohen's d effect size of 0.59. The PANAS negative-affect measure also favored saffron, with P = 0.043 and Cohen's d = 0.55. These findings provide two related pieces of evidence that the extract may have influenced how participants rated certain difficult emotional experiences during the 12 weeks. They do not mean every participant experienced the same degree of improvement.

The researchers also examined anxiety- and depression-related items within the GCS psychological measure. Between baseline and week 12, those scores fell by 33% and 32%, respectively, in the saffron group. In the placebo group, anxiety scores rose by 7%, while depression-related scores declined by 9%. These are changes in questionnaire scores, not the proportion of women whose anxiety or depression disappeared. Nor do they show that the extract treated a diagnosed psychiatric disorder, since the study excluded women with many relevant medical and treatment histories.

For someone trying to understand those numbers, the important comparison is between groups rather than the largest percentage quoted by itself. Some of the saffron group's psychological improvement might have occurred from being in a study, changing expectations, or natural symptom variation. The placebo group helps account for those influences. Even when a difference is statistically significant, it remains an average across participants, and a moderate effect size does not tell an individual how she will feel next month. Future trials with a broader population would help determine how consistent the signal is.

Did Saffron Help Hot Flashes or Night Sweats?

The study did not establish that the saffron extract performed better than placebo for vasomotor complaints, the category that includes hot flashes and night sweats. The between-group P value was 0.401, far above the conventional 0.05 threshold for statistical significance. Participants in both groups reported reductions in vasomotor scores over time, but the differences in their patterns of change were not convincing. It would therefore be inaccurate to present this trial as evidence that saffron reliably reduces hot flashes or nighttime sweating.

The result is understandable when different symptoms are considered separately. Feeling emotionally unsettled during the menopausal transition is not the same process as experiencing sudden heat, flushing, or perspiration. Those experiences may overlap and influence one another, particularly when nighttime symptoms disturb sleep, but an ingredient associated with selected mood scores cannot automatically be assigned a benefit for body-temperature regulation. The trial also failed to demonstrate a significant between-group difference in somatic or physical symptoms, which had P = 0.589.

Research from other populations has sometimes examined saffron for vasomotor symptoms, including smaller trials involving postmenopausal women. Those studies cannot simply be substituted for the 2021 perimenopause results, because participants, severity of symptoms, extract preparations, and study methods differed. The Menopause Society's 2023 position statement did not recommend herbal supplements as evidence-based interventions for vasomotor symptoms. Women whose chief concerns are persistent hot flashes or sleep-disrupting night sweats can ask a clinician about management approaches supported specifically for those symptoms rather than relying on an unrelated mood finding.

What Did the Primary Outcome Show?

The most important statistical caution is the result for the GCS total score, the trial's primary outcome. In the repeated-measures analysis, the difference in how saffron and placebo scores changed over time produced P = 0.078. That did not reach the commonly used 0.05 threshold. The investigators also reported a separate baseline-to-week-12 percentage-change comparison that favored saffron: total scores fell 32% in the saffron group and 14% with placebo, with P = 0.027 for that analysis. Both belong in an accurate account.

A P value describes how unusual a result would be under a particular statistical model if there were no real group effect; it is not the probability that the supplement works, nor is crossing 0.05 a guarantee of clinical importance. It also matters that the study examined multiple outcomes. The more comparisons researchers make, the more carefully isolated significant results should be assessed. The positive psychological subscale finding remains relevant, but it cannot convert an inconclusive primary result into proof of improvement across the entire spectrum of menopausal complaints.

For everyday decisions, this is the difference between a useful research signal and a product promise. A reader can reasonably say that one standardized saffron extract showed favorable effects on selected self-reported psychological scores. She cannot reasonably conclude from the same trial that saffron will relieve every symptom of perimenopause, restore hormone levels, or replace established care. This boundary is not a technicality; it prevents a statistic collected from a specific group of women from being stretched beyond the question it was designed to answer.

How Reliable Is the Evidence?

The 2021 study offers useful but limited human evidence. Its randomization, blinding, placebo comparison, prospective registration, and established questionnaires strengthen the findings. However, its small sample, selected participants, short follow-up, multiple measurements, and manufacturer funding restrict how confidently the results can be generalized. A separate 2026 trial adds mood-related evidence in older women, but it was not a direct replication of the perimenopause study.

What Did the Placebo Comparison Reveal?

The placebo group illustrates why improvement after taking a supplement is not the same as improvement caused by the supplement. The total GCS score fell over time in both groups, indicating that participants reported feeling better even when they had received inactive tablets. Symptoms might naturally fluctuate over 12 weeks, while regular assessments, heightened attention to health, and expectations surrounding a study can affect the way people describe their experiences. A credible intervention finding must therefore rest on a sufficiently convincing difference between groups, not merely a before-and-after change.

On the main overall symptom comparison, that difference was not statistically significant. Yet the psychological subscale did produce a significant group difference, as did the negative-affect measure. Reading these results together paints a more useful picture than choosing whichever result looks most impressive. The extract may have influenced a narrower set of reported experiences, while the evidence was insufficient to establish a broad effect on menopausal symptoms. This is a reasonable interpretation of a mixed result, not an argument for ignoring either the positive or negative findings.

There were also checks on whether participants could identify their assignment. At the end of the trial, only 8% of the saffron group and 28% of the placebo group correctly guessed which tablets they had received. Those figures suggest that treatment concealment was relatively effective, limiting one potential source of bias. Still, blinding and randomization do not eliminate every influence, and a study using self-report measures cannot reveal the exact biological reason for an improvement in score. Replication by independent teams would make the overall picture clearer.

What Were the Study's Limitations?

A total of 86 randomized participants is modest for a question as broad as menopausal health. The study was powered using assumptions about its main symptom scale, but smaller samples can yield imprecise estimates and may fail to identify uncommon adverse effects. Seventy-six women completed all study requirements, while analyses included some earlier questionnaire data from women who did not complete the full intervention. The published method carried forward available week-four observations for missing later values, an approach that relies on assumptions about what would otherwise have happened over time.

Menopausal stage is another important limitation. Eligibility relied substantially on participants' reports of menstrual changes, without a comprehensive medical and hormonal assessment for every woman. The authors acknowledged that participants in different reproductive stages could therefore have been included. The exclusion of women with many medical conditions, severe psychiatric symptoms, or ongoing relevant treatments also narrows the applicability of the findings. Someone using hormone therapy, an antidepressant, or other regular medication should not assume the study established the same balance of benefits and risks for her circumstances.

The 12-week duration leaves questions about longer-term use, and the main questionnaires were designed to capture perceived symptoms rather than directly diagnose clinical depression or measure sex-hormone changes. Several outcomes and additional analyses were examined, so isolated favorable P values need cautious interpretation. The trial was funded by Pharmactive Biotech Products, which supplied the ingredient; the publication disclosed that relationship and stated that the sponsor was not involved in study design, analysis, or manuscript preparation. Funding does not automatically invalidate research, but independent trials would strengthen confidence in findings tied to a commercial extract.

How Does the 2026 Saffron Trial Compare?

In June 2026, Frontiers in Nutrition published another randomized, double-blind, placebo-controlled trial of affron® involving 86 women aged 50–70 who reported low mood and poor sleep. Participants received 28 mg daily or placebo for 12 weeks. The primary outcome was the depression subscale of the Depression, Anxiety and Stress Scale-21, or DASS-21. Saffron showed a significant advantage on that measure, with an adjusted mean difference of 2.37 points, a 95% confidence interval of 0.23–4.51, P = 0.030, and Cohen's d = 0.48.

The newer trial also reported improvements in self-esteem and sleep-related impairment compared with placebo, while its direct sleep-disturbance measure did not show a significant group difference, with P = 0.786. Similarly, no significant differences appeared for the exploratory appearance-related outcomes. A threshold for substantial improvement on the depression questionnaire was reached by 48.8% of the saffron group versus 25.6% of placebo recipients. These findings are relevant, but the research population was selected for low mood and poor sleep, not specifically for confirmed perimenopause.

Because these trials examined different questions, the newer findings do not retroactively make the 2021 primary outcome statistically significant. They do add to a developing body of research on standardized saffron extracts and selected emotional measures in middle-aged and older women. Both trials also involved the same named ingredient and reported commercial relationships, so the need for independent replication remains important. Readers can compare the 2021 original publication with the 2026 original publication to see the populations and endpoints for themselves.

What Dose and Safety Were Studied?

In the 2021 trial, women received 28 mg of standardized affron® extract each day, divided into two 14 mg tablets, for 12 weeks. No major adverse events were reported, although mild complaints occurred and one saffron participant withdrew with digestive discomfort. The study provides limited short-term tolerability information for a selected population; it does not establish an ideal personal dose or guarantee safety with other supplements or medications.

How Much Saffron Was Used?

The active tablets supplied 14 mg of a standardized saffron extract twice daily, once in the morning and once in the evening, for a total of 28 mg. The extract came from the stigmas of Crocus sativus L. and was standardized to more than 3.5% Lepticrosalides®, a manufacturer-defined measure involving saffron constituents. The tablets were taken with or without food according to trial instructions. Those details describe the research intervention precisely; they are not a universal set of directions for consumers purchasing different products.

Standardization matters because saffron is a plant material rather than a single chemical compound. Whole stigmas used as a spice, milled saffron powder, and concentrated extracts may have different constituent profiles. Extraction processes, plant authenticity, manufacturing controls, and ingredient specifications influence what a given milligram figure actually represents. A bottle labeled “saffron extract 30 mg” is not automatically comparable to a trial using affron® 28 mg, even when the printed amounts look close. Similar labels cannot establish identical composition, absorption, or results.

The two discussed trials each lasted 12 weeks and used 28 mg daily, but they did not identify a minimum effective dose, a maximum useful dose, or an optimal schedule for everyone. Taking more is not known to improve the studied outcomes and could introduce additional risk. When reading supplement information, it is more helpful to match the named ingredient, stated amount per serving, and documented standardization than to chase a single headline number. Actual use should follow the verified finished-product label and an individual's professional guidance where relevant.

What Side Effects Were Reported?

The 2021 paper reported no major adverse events but did document mild complaints. Across the saffron group, researchers recorded 11 adverse-event reports, compared with nine in the placebo group. These totals count reported events, not necessarily distinct people, because one participant may report more than one problem. In the saffron group, reports included flatulence on three occasions, nausea or bloating on two occasions, and headache or migraine on two occasions. Other individual complaints were less frequent, and the authors noted a possible tendency toward more digestive complaints with saffron.

One woman receiving saffron withdrew because of digestive discomfort or bloating, while one placebo recipient withdrew because of nausea. Since symptoms also occurred with placebo, and the groups were small, the trial cannot establish precisely how frequently each possible side effect would arise in a larger population. In addition, the investigators excluded many people taking regular medicines or managing certain health conditions. The absence of serious reported events over 12 weeks is reassuring within those narrow circumstances but does not demonstrate that all saffron supplements are risk-free.

Safety depends on more than the botanical name. Formulation, dose, contaminants, allergies, medical history, pregnancy potential, and interactions with medicines all deserve consideration. Someone who develops unexpected symptoms while using a supplement should not assume that a “natural” label means the product cannot be involved. Likewise, a consumer planning to use saffron for months or years cannot treat one 12-week trial as long-term safety evidence. Discussing relevant medicines and health conditions with a clinician or pharmacist remains the sensible approach when there is uncertainty.

Is the Studied Dose Right for Everyone?

There is no basis in these trials for prescribing 28 mg of saffron to every woman experiencing perimenopause. Research doses are selected for a particular ingredient, population, and study goal. The 2021 participants generally did not use ongoing medications and did not have several excluded medical conditions. Its findings therefore do not directly establish suitability for someone taking an antidepressant, sedative, blood-pressure medicine, hormonal treatment, or a complex combination of supplements. Potential interactions should be checked individually rather than guessed from the fact that saffron is used in food.

Pregnancy potential also matters. Irregular menstrual cycles during perimenopause do not necessarily mean pregnancy is impossible, and the trial did not establish safety during pregnancy or breastfeeding. Women who are pregnant, could become pregnant, or are breastfeeding should not extrapolate reassurance from this selected adult trial. A healthcare professional can consider reproductive circumstances and other medical factors when discussing an unfamiliar botanical ingredient.

It is equally worth examining what is already in the supplement cabinet. A woman may take separate magnesium, vitamin B6, calming botanicals, and a blended liquid formula without realizing she is duplicating ingredients. A careful review of Supplement Facts, amounts per serving, directions, and other products helps avoid that problem. The purpose is not to make a daily wellness routine complicated; it is to remove uncertainty before adding something new. Persistent low mood, unusual bleeding, or sleep disruption that interferes with life warrants an appropriate clinical assessment rather than a self-directed experiment based on a single paper.

What Do the Findings Mean for Women?

For women considering saffron, the research suggests a possible benefit on selected psychological symptom scores, but it does not establish comprehensive perimenopause relief. The practical lessons are to identify the symptom being investigated, compare the studied extract with a product's ingredient specifications, review safety considerations, and keep expectations realistic. A well-labeled supplement may support informed shopping, but a trial on one extract is not proof for every finished formula.

Which Benefits Have Supporting Evidence?

The most relevant evidence from the 2021 trial concerns psychological symptom scores and negative affect, not the full range of menopausal changes. The separate 2026 study also found a significant difference on a depression-related questionnaire among older women with low mood and poor sleep. Together, these results justify continued investigation of standardized saffron extracts in relation to selected emotional outcomes. They do not demonstrate that saffron treats clinical depression, corrects reproductive hormones, prevents menopausal changes, or replaces medical care when symptoms are persistent or severe.

The distinction becomes clearer when thinking about daily experiences. Someone who feels irritable after a difficult week, sleeps less during a stressful period, and notices changing menstrual cycles may have several overlapping influences on how she feels. A self-reported mood score captures part of that experience, but it does not identify the underlying cause. Sleep habits, physical activity, personal stress, medical issues, and menopausal stage may all be relevant. No single ingredient should be expected to resolve all these factors, regardless of how appealing an advertisement sounds.

It is also important to avoid carrying positive findings from one symptom category into another. The 2021 study did not show a clear advantage for hot flashes or somatic complaints, and the 2026 trial did not show a significant difference on its sleep-disturbance measure. Women whose primary concerns are vasomotor symptoms, substantial sleep loss, or persistent emotional distress should discuss options that address those specific concerns. Botanical research can inform curiosity and purchasing decisions, but the relevant endpoint must match the actual need before a study becomes useful evidence.

Do All Saffron Supplements Match the Trial?

No. The study evaluated affron®, a named standardized extract, while retail products can use different saffron powders, extracts, supplier specifications, or combinations. An ingredient label that simply says “saffron” may provide little information about processing or chemical consistency. Even a clearly declared amount per serving cannot establish equivalence if the extraction and standardization differ. This is especially important with botanicals, because differences in sourcing and manufacturing can affect the profile of naturally occurring constituents in the finished material.

The distinction becomes more important when saffron is combined with other ingredients. A formula that includes L-theanine, magnesium, or vitamin B6 may be designed for a broader everyday wellness routine, but its results cannot be borrowed from a saffron-only tablet trial. AirVigor's cranberry-flavored Saffron Liquid Sticks, for example, combine saffron extract with additional ingredients in a portable liquid format. That is a separate finished formulation, and the 2021 and 2026 studies did not test the AirVigor product. A consumer should assess its current label and ingredient information on their own terms rather than assume it contains the exact patented extract investigated in those publications.

Good product information helps make these differences visible. A useful label identifies serving size, ingredient amounts where disclosed, directions, and any verified sourcing or standardization claims. It should not use a clinical-study logo, a research percentage, or the words “clinically proven” to imply that an untested finished product produced the same result. A brand can communicate clearly about ingredient research while also being candid about the limits of the connection. That kind of precision is more valuable than making every formula sound identical to a clinical intervention.

How Can Women Make Informed Choices?

Start with the question you are actually trying to answer. If your main concern is occasional emotional strain, look for research that measured psychological experiences. If frequent night sweats are the priority, a trial focused on mood provides limited guidance. Next, examine who participated, how long the intervention lasted, which product was studied, and whether the main comparison was favorable. Those details will often tell you more than a large percentage placed on the front of a product page.

There are a few practical checks worth making before adding a botanical supplement to a routine:

• Match the concern to the outcome. Mood questionnaires, sleep scores, and hot-flash ratings measure different things; do not treat them as interchangeable evidence.
• Read the full Supplement Facts panel. Check the actual serving amount, additional ingredients, and whether you already take overlapping nutrients or botanicals.
• Compare ingredient identities. A standardized branded extract and a generic saffron preparation are not automatically interchangeable because their milligram amounts resemble one another.
• Look for the comparator. A reduction from baseline is less informative than a difference from placebo, particularly for symptoms that can fluctuate naturally.
• Check personal circumstances. Pregnancy potential, medication use, medical conditions, and unusual reactions deserve individual professional guidance.
• Keep a realistic record. Notes on sleep, stress, cycle changes, and day-to-day well-being may make conversations with a clinician more specific, even though they cannot prove causation.

A practical routine also needs to fit normal life. Form, flavor, portability, clear directions, and storage requirements can influence whether a supplement is easy to use consistently, but convenience is not evidence that it works. The most useful shopping decision balances those everyday details against ingredient transparency and honest statements about research. For women navigating perimenopause, this approach protects against both exaggerated promises and the equally unhelpful idea that an early study has nothing to teach us. Evidence is valuable precisely when its strengths and limitations are kept together.

Research Sources: Lopresti and Smith, 2021, Journal of Menopausal Medicine; Lopresti and Smith, 2026, Frontiers in Nutrition; The Menopause Society, 2023 Nonhormone Therapy Position Statement.

The 2021 saffron perimenopause trial deserves attention for its controlled design and its encouraging findings on selected psychological symptom measures. It also deserves careful reading because its principal overall symptom analysis was not statistically significant and the trial did not establish benefits for hot flashes or other physical symptoms. The 2026 study adds context for mood-related outcomes in older women, but it does not resolve every question about menopausal stage, long-term use, or different saffron preparations. For consumers, the most useful conclusion is neither “saffron works for menopause” nor “the research proves nothing.” It is that one particular extract has produced some promising, limited human evidence, and informed choices require matching those findings to the right product, person, and concern.

Frequently Asked Questions

1. Does saffron help with perimenopause symptoms?

A 2021 randomized trial found that a standardized saffron extract was associated with greater improvements than placebo on certain psychological symptom scores in women reporting perimenopausal complaints. It did not establish a significant advantage for the main repeated-measures analysis of overall menopausal symptoms, hot flashes, or other physical complaints. That means the study may be relevant to questions about mood-related measures, but it does not justify a broad claim that saffron relieves perimenopause as a whole. Symptoms that disrupt daily life deserve individual assessment rather than reliance on a single botanical ingredient.

2. What was the saffron dose in the perimenopause clinical trial?

The 2021 study used 28 mg of standardized affron® saffron extract each day, divided into two 14 mg tablets, for 12 weeks. Participants took the tablets in the morning and evening, with or without food. This is a description of the research intervention, not a personalized dosing recommendation. Other saffron supplements may contain different extracts and additional ingredients, so a matching number of milligrams does not guarantee equivalent composition or effects. Consumers should use verified product directions and seek professional advice when medical circumstances or medications make suitability uncertain.

3. Did the saffron study show an improvement in anxiety or depression?

Researchers reported a 33% decline in anxiety-related questionnaire scores and a 32% decline in depression-related scores from baseline to week 12 in the saffron group. Some between-group psychological comparisons also reached statistical significance, including the GCS psychological subscale at P = 0.032. These were changes in self-reported scale scores among selected participants, not cure rates and not proof that saffron treats diagnosed anxiety or depressive disorders. The study excluded women with several psychiatric conditions or treatments, so clinical care remains important when symptoms are persistent, severe, or affecting safety and daily functioning.

4. Is saffron effective for hot flashes and night sweats?

The 2021 perimenopause trial did not find a statistically significant advantage over placebo for vasomotor symptoms, the category covering hot flashes and night sweats. The between-group P value was 0.401, and both groups reported some improvement over time. This trial therefore does not support a confident claim that saffron improves those symptoms. Other smaller studies have examined related questions in different populations, but they should not be treated as direct replacements for this result. Women troubled by frequent hot flashes or nighttime sweating can discuss evidence-based management choices with a healthcare professional.

5. Is taking saffron for 12 weeks safe?

In the 2021 study, the standardized saffron extract was generally well tolerated and no major adverse events were reported, although participants experienced some mild complaints and one saffron recipient withdrew because of digestive discomfort. The trial involved a relatively small, carefully selected population, making it unsuitable for ruling out uncommon reactions or establishing safety with long-term use. It also did not adequately assess everyone taking prescription medications, those with excluded medical conditions, or pregnant or breastfeeding individuals. Safety needs to be considered in relation to the exact formulation, individual circumstances, and potential interactions rather than inferred from the ingredient's culinary history.

6. Is the 2026 saffron trial the same as the 2021 perimenopause study?

No. Both studies used 28 mg daily of a standardized affron® extract for 12 weeks, and both randomized 86 women, but they recruited different populations and asked different primary questions. The 2021 study focused on women aged 40–60 reporting perimenopausal complaints and used total GCS symptoms as its primary outcome. The 2026 study recruited women aged 50–70 with low mood and poor sleep and measured depression-related DASS-21 scores as its primary outcome. Its positive primary result provides related evidence about mood measures but does not turn the older study's nonsignificant primary result into a positive one.